Zymeworks BC Inc ZYME

NAS: ZYME | ISIN: US98985Y1082   16:45
9,210 USD (+0,99%)
(+0,99%)   16:45

2 mei 2024 · Zymeworks Provides Corporate Update and Reports First Quarter 2024 Financial Results · Persbericht

30 april 2024 · Zymeworks Announces Participation in Upcoming Investor Conferences · Persbericht

8 april 2024 · Zymeworks Presents New Data from Multiple Preclinical Development Programs at 2024 American Association for Cancer Research Annual Meeting · Persbericht

28 maart 2024 · Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors · Persbericht

27 maart 2024 · Zymeworks Announces Participation in Upcoming Investor Conferences · Persbericht

5 maart 2024 · Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate and Multispecific Platforms at the American Association for Cancer Research Annual Meeting · Persbericht

27 februari 2024 · Zymeworks Announces Participation in Upcoming Investor Conferences · Persbericht

8 februari 2024 · Zymeworks Announces Appointment of Dr. Alessandra Cesano to its Board of Directors · Persbericht

31 januari 2024 · Zymeworks Announces Participation in Upcoming Investor Conferences · Persbericht

4 januari 2024 · Zymeworks Outlines Strategic Priorities and Outlook for 2024 and 2025 · Persbericht

4 januari 2024 · Zymeworks Announces Additional Leadership Appointments · Persbericht

26 december 2023 · Zymeworks Announces $50 Million Private Placement to EcoR1 Capital · Persbericht

15 december 2023 · Zymeworks Added to Nasdaq Biotechnology Index · Persbericht

30 november 2023 · Zymeworks Announces Participation in Upcoming Investor Conference · Persbericht

3 juni 2023 · Jazz Pharmaceuticals and Zymeworks Present Positive Pivotal Phase 2b Trial Data at ASCO 2023 Evaluating Zanidatamab in HER2-Amplified Biliary Tract Cancers · Persbericht

21 december 2022 · Jazz Pharmaceuticals and Zymeworks Announce Jazz has Confirmed Opt-in and Advances Partnership for Zanidatamab · Persbericht

Mijn selecties